Skip to main content
Fig. 2 | Systematic Reviews

Fig. 2

From: Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

Fig. 2

Pain. A Mean improvement in the weekly average of patients’ 24-h pain scores on an 11-point Likert-type scale at ≤ 12 weeks. B Mean improvement in pain severity assessed using the Brief Pain Inventory scale: average pain scores at ≤ 12 weeks. C Number of patients with ≥ 50% improvement in the weekly average of 24-h pain scores on the 11-point Likert-type scale at ≤ 12 weeks. D Number of patients with ≥ 30% improvement in the weekly average of 24-h pain scores on the 11-point Likert-type scale at ≤ 12 weeks. E Mean improvement in patients’ night pain scores on the 11-point Likert-type scale at ≤ 12 weeks. F Mean improvement in patients’ worst pain scores on the 11-point Likert-type scale at ≤ 12 weeks

Back to article page